Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

• Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

• The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA.

• Omeros concurrently requested a Type A meeting with FDA to resolve any outstanding items.

• Related Link: Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA.

• Narsoplimab is the first drug candidate submitted to FDA for approval in HSCT-TMA.

• It has Breakthrough Therapy and Orphan designations in both HSCT-TMA and IgA nephropathy.

• Related: Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years.

• Price Action: OMER shares are up 1.94% at $5.26 during after-hours trading on Wednesday.

See more from Benzinga

• Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

• Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.